ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2010 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops targeted anticancer products, today announced that the Company will host a conference call at 4:30 p.m. ET on Wednesday, August 4, 2010, to discuss ImmunoGen’s financial results for the three-month period and fiscal year ended June 30, 2010. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-0379. Passcode 4241333. The call also may be accessed through the Investor Information section of the Company’s website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through August 11, 2010.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses engineered antibodies to deliver one of ImmunoGen’s proprietary cancer-cell killing agents specifically to tumor targets. In addition to the Company’s product pipeline, compounds are in clinical testing through ImmunoGen’s collaborations with Genentech (a member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. A marketing application for the most advanced compound using ImmunoGen’s TAP technology, T-DM1, was submitted to the US FDA by Genentech in July 2010. Other ImmunoGen collaborative partners include Bayer Schering Pharma AG and Amgen. More information about ImmunoGen can be found at www.immunogen.com.



CONTACT:

Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
[email protected]
Executive Director, Investor Relations and Corporate Communications
or
Media:
The Yates Network
Adriana Jenkins, 617-744-1713

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.